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Abstract A multicomponent DNA vaccine, encoding
Toxoplasma gondii GRA1 and SAG1, was constructed and
tested for its ability to confer protection. BALB/c mice were
challenged with tachyzoites of the virulent T. gondii RH
strain at 4 weeks following the last immunization, and
immune responses and survival times were observed. The
results show that vaccination by the multicomponent vac-
cine prolonged survival of mice challenged with the T.
gondii RH strain (from average 4.50±0.22 to 7.60±
0.74 days); induced high levels of IgG antibody (from
0.252±0.080 to 0.790±0.083), IFN-gamma (from 598.74±
67.50 to 853.77±66.74 pg/ml), and IL-2 (from 89.44±10.66
to 192.24±19.90 pg/ml); changed the CD4+/CD8+ lympho-
cyte ratio (from 1.81±0.14 to 1.09±0.19); and stimulated
NK cell-killing activity (from 46.81±3.96 to 64.15±
7.71 %). These findings demonstrate that a multicomponent
DNA vaccine, encoding GRA1 and SAG1, primes a strong
humoral and cellular immune response and enhances pro-
tection against T. gondii challenge. The new, combined
DNA vaccine provides another means to combat T. gondii
infection.
Introduction
Toxoplasma gondii is an intracellular protozoan parasite that
causes significant morbidity and mortality in congenitally
infected and immunocompromised individuals. In humans,
this relatively benign infection may reactivate under condi-
tions of immunosuppression, such as in HIV-infected indi-
viduals and cancer patients, resulting in Toxoplasma
encephalitis and other complications (Calabrese et al.
2008; Kato et al. 2005; Scorza et al. 2003). T. gondii
infection acquired by pregnant women and its transmission
to the fetus continue to be the cause of tragic yet preventable
disease (Montoya and Remington 2008), and it is associated
with transplacental infection. In veterinary medicine, T.
gondii infection has economic impact by inducing abortion
and neonatal loss in sheep and goats and is a source of
transmission to humans (Dubey 1990). Therefore, the de-
velopment of an effective vaccine against T. gondii would
be of great value to both human and veterinary medicine.
Recently, there have been efforts to develop anti-T. gon-
dii vaccines (Bhopale 2003). Among the new approaches,
DNA vaccines have become a focus since they elicit potent,
long-lasting humoral and cell-mediated immunity (Alarcon
et al. 1999). Membrane-associated surface antigens (SAG1
and SAG2), secreted dense-granule proteins (GRA1, GRA2,
GRA4, and GRA7), rhoptry proteins (ROP1 and ROP2),
and micronemal proteins (MIC1, MIC2, MIC3, MIC4, and
MIC8) are all putative T. gondii vaccine candidates (Dautu
et al. 2007; Fang et al. 2009; Jongert et al. 2007; Li et al.
2011; Liu et al. 2010, 2009; Wang et al. 2009; Xue et al.
2008; Zhang et al. 2007). These antigens have shown certain
protection, increased survival time of animals, and a reduced
number of brain cysts in rodents. Also, employment of
different forms of adjuvant was evaluated and compared
the effects on the immune response stimulated by DNA
vaccine (Khosroshahi et al. 2012).
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SAG1 is the best-characterized candidate vaccine.
Previous studies have shown that DNA vaccines with
SAG1 induce both humoral and cellular immune responses
and partial protection against T. gondii (Couper et al. 2003;
Fachado et al. 2003; Liu et al. 2009; Mevelec et al. 2005;
Xue et al. 2008; Zhang et al. 2007). Dense-granule antigens
(GRA), secreted in abundance, are major components of
both the vacuole-surrounding tachyzoites and the cyst
wall-surrounding slower growing bradyzoites (Cesbron-
Delauw 1994). Therefore, the GRAs may be important
protective antigens. Among the GRAs, GRA1, a product
of T. gondii tachyzoites and bradyzoites, is a promising
candidate. A GRA1 DNA vaccine can prime an anti-
Toxoplasma immune response (Bivas-Benita et al. 2003;
Jongert et al. 2007; Vercammen et al. 2000). In addition,
native protein encoded by GRA1 is a type of Ca2+-binding
protein that functions to activate or stabilize the reticulum
structure and may also function as a Ca2+ buffer (Lin et al.
2010). GRA1 and SAG1 possess distinct antigenicity, and
their expression spans different stages of T. gondii develop-
ment. Therefore, the objectives of this study were to con-
struct eukaryotic expression plasmids, pVAX1-GRA1 and
pVAX1-SAG1, and to evaluate the immune response and
protective effect of a combined DNA vaccine in BALB/c
mice against challenge with a highly lethal T. gondii RH
strain. The results show that a multicomponent DNA vac-
cine, encoding T. gondii GRA1 and SAG1, primed a strong
humoral and cellular immune response and enhanced pro-
tection against T. gondii challenge.
Materials and methods
Cell lines, plasmids, mice, and reagents
Raw264.7 cell, a murine macrophage cell line, was obtained
from the Shanghai Cell Biological Institute (Shanghai,
China). Eukaryotic expression vector pVAX1 was pur-
chased from Invitrogen (Carlsbad, CA, USA). SPF grade
BALB/c mice were purchased from Shanghai SLAC
Laboratory Animal Co., Ltd. (Shanghai, China).
Taq DNA polymerase (high fidelity) was purchased from
Stratagene (Santa Clara, CA, USA). Restriction enzymes
(EcoR I and Kpn I), calf intestine alkaline phosphatase, and
T4 DNA Ligase were purchased from New England Biolabs
(Beverly MA, USA). Endonuclease-Free Plasmid Mega kit
was from QIAGEN (Hilden, Germany). Liposome
(Lipofectamine 2000), and kanamycin were obtained from
Invitrogen. Mouse anti-T. gondii SAG1 and rabbit anti-T. gon-
dii trophozoite antibodies were from Biodesign (Saco ME,
USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
(MTT) was obtained from Sigma (St. Louis, MO, USA).
Fluorescein isothiocyanate (FITC)-labeled anti-mouse CD4
antibody, polyethylene (PE)-labeled anti-CD8 antibody was
from Beckman Coulter (Shanghai, China). Detection kits for
mouse IFN-γ, IL-2, and IL-4 cytokines (OptEIA™) were from
BD Bioscience Corp (Shanghai, China).
Primers
The following primers were used: GRA1VAXF, 5′CGG
GGTACCATGGTGCGTGTGAGCGCTATTG (Kpn I);
GRA1VAXR , 5 ′ CCGGAATTCTTACTCTCTC
TCTCCTGTTAGG (EcoR I ) ; SAG1VAXF, 5 ′
CGGGGTACCATGTCGGTTTCGCTGCACCAC (Kpn I);
and SAG1VAXR, 5′ CCGGAATTCTCACGCGACACAA
GCTGCG (EcoR I).
Amplification of GRA1 and SAG1 genes
GRA1 or SAG1 was amplified from recombinant plasmid
pCMV/myc-GRA1 or pCMV/myc-SAG1 (constructed in
our previous project) templates, respectively. Briefly, sam-
ples were denatured for 5 min at 94 °C, followed by 30
cycles of denaturation (94 °C, 30 s), with annealing (55 °C,
30 s) and extension (72 °C, 1 min), followed by a final
extension at 72 °C for 10 min. PCRs were performed with
the primer pairs GRA1VAX F-R or SAG1VAX F-R.
Construction of the recombinant plasmids pVAX1-GRA1
and pVAX1-SAG1 and large-scale DNA preparation
PCR products were cloned into the pVAX1 vector. Sequencing
was performed on an ABI PRISM genetic analyzer in Takara
Biotechnology (Dalian, China) using primers T7 (F) and BGH
(R). Sequence alignments were done using BLAST with de-
fault settings (PubMed, http://blast.ncbi.nlm.nih.gov). All plas-
mids were propagated in Escherichia coli DH5-α.
The plasmids pVAX1-GRA1 and pVAX1-SAG1 were
purified by Endo-Free Plasmid Mega kit prior to using for
vaccination and dissolved in sterile endotoxin-free
phosphate-buffered saline (PBS). Plasmid integrity was
checked by agarose gel electrophoresis after digestion with
appropriate restriction enzymes. The DNA concentration
and purity was determined by A260.
Macrophage transfection by liposome and gene expression
One day before transfection, RAW264.7 was inoculated into
six well plates (Corning Incorporated, Corning, NY, USA)
with 2-ml common culture medium and cultured in 5 % CO2
at 37 °C to 80 % confluence. Five micrograms DNA
(pVAX1-GRA1, pVAX1-SAG1, or pVAX1) were diluted
in 50-μl sera-free medium (10 μl liposome diluted in 40-
μl serum-free medium) and mixed. DNA and liposomes
were incubated for 20 min at room temperature to form
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DNA–liposome complexes. Transfection mixture (100 μl)
was added to the macrophage culture and gently mixed. The
plates were then incubated in 5 % CO2 at 37 °C for 48 h.
GRA1 and SAG1 expression was detected by immunohis-
tochemistry. Briefly, RAW264.7 (transfected by pVAX1-
GRA1, pVAX1-SAG1, empty control plasmid pVAX1, or
nontransfected), grown on the cover slip, was fixed by pre-
chilled 70 % alcohol for 30 min. Cells were rinsed three times
with PBS for 3 min, incubated with 50μl peroxidase-blocking
solution for 10 min, and rinsed three times with PBS.
Nonimmune serum was incubated for 10 min, and the surplus
was discarded. Primary antibody (50 μl) was then incubated
for 60 min, rinsed three times with PBS, and followed by
50 μl biotin-conjugated secondary antibody for 10 min and a
rinse with PBS (three times). Complexes were visualized by
incubation with 50 μl streptavidin peroxidase solution for
10 min, PBS rinse (three times), and addition of 100 μl freshly
prepared DAB for 3–10 min. Following a wash by double
distilled water, samples were counterstained by hematoxylin
and washed by PBS. Unless noted, all incubations and washes
were performed at room temperature. Samples were photo-
graphed using the Leica photo system (Solms, Germany).
Vaccination
BALB/c mice were randomly divided into five groups of 18
each. Plasmids were diluted to 2 μg/μl in PBS. The five
groups were: 50 μl PBS, 100 μg empty pVAX1 vector,
100 μg pVAX-GRA1, 100 μg pVAX1-SAG1, and 50 μg
pVAX1-GRA1 + 50 μg pVAX1-SAG1, respectively. Each
group received three injections (separated by 2-week inter-
vals) in both tibias and anterior muscles. Injections were
administered with a 0.3-ml syringe.
Challenge experiments
Four weeks after the last vaccination, ten mice were selected
randomly from each group and challenged by intraperitone-
al injection with 105 tachyzoites of T. gondii RH strain. The
length of survival was recorded.
Evaluation of the humoral immune response
IgG antibodies were monitored by ELISA. The eyes were
extirpated to get sera from mice 4 weeks after the third
vaccination. Ninety-six-well plates were coated with tachy-
zoite lysis antigen of T. gondii. Serum samples were diluted
(1:100) prior to testing.
Evaluation of the cellular immune response
ELISA was used to measure IFN-γ, IL-2, and IL-4 concen-
trations. The ratio of CD4+/CD8+ in spleen cells was
measured by Beckman Coulter XL flow cytometry
(488 nm excitation, 620 nm emission for PE, and 525 nm
for FITC), using 0.5×106 cells.
NK cell-killing activity
Splenocytes (effector cells) obtained from mice 4 weeks
after the third vaccination were adjusted to 5×106/ml in
RPMI 1640 with 5 % fetal bovine serum. The eugenic
Yac-1 cells (target cells) were adjusted to 2×105/ml in
RPMI 1640. Effector and target cells were plated in 100 μl
96-well flat-bottomed plates at E/T ratios of 25:1. Effector
and target cells, alone in RPMI 1640, served as controls. All
assays were done in triplicate. After a 44-h incubation at
5 % CO2 and 37 °C, 20 μl MTTwas added to each well and
further incubated at 5 % CO2, 37 °C for 4 h. Excess super-
natant was discarded, and 100 μl 100 % DMSO was added
to each well, and mixed for 10 min, and the A570 was
measured. Cytotoxicity (in percent) 0 [(experimental − ef-
fector spontaneous) / target spontaneous] × 100.
Results
The construction of DNA vaccines and identification
and expression in macrophages
A 573-bp PCR product, corresponding to the GRA1 coding
sequence, was generated, digested with the appropriate
restriction enzymes, and cloned into the expression vector
pVAX1, generating pVAX1-GRA1. A 960-bp PCR product
for SAG1 was created the same way as for GRA1, generat-
ing pVAX1-SAG1. Sequence alignment for both GRA1 and
SAG1 by PubMed verified that the sequence was correct.
Figure 1 shows the identification of recombinant plasmid
pVAX1-GRA1, pVAX1-SAG1 by PCR, and restriction
enzyme digestion.
To determine whether the T. gondii GRA1 and SAG1
proteins were expressed in RAW264.7, following transfec-
tion with pVAX1-GRA1, pVAX1-SAG1, or an empty
vector, expression was tested by immunohistochemistry.
Brown-stained particles were found in the cytoplasm that
had been transfected by pVAX1-GRA1 or pVAX1-SAG1.
No stain was observed in cells transfected with control
vector pVAX1 (Fig. 2).
Protective effect of GRA1 and SAG1 DNA vaccine
in BALB/c mice challenged with T. gondii
To test whether the DNAvaccine, encoding T. gondii GRA1
and SAG1, could protect against a lethal T. gondii infection,
BALB/c mice were immunized with 100 μg pVAX1 empty
vector, 100 μg pVAX-GRA1, 100 μg pVAX1-SAG1, or
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50 μg pVAX1-GRA1 + 50 μg pVAX1-SAG1, respectively.
The survival time is shown in Fig. 3. Control mice died
beginning on day 3, and all mice had died by day 5. The
mice lived on average, just 4.50±0.22 days, following in-
fection. Mice immunized with pVAX1 died beginning on
day 3, and all had died by day 6, with an average of 4.80±
0.29 days. The mice of the pVAX1-GRA1 group died be-
ginning on day 3, and all had died by day 5, with an average
of 4.10±0.28 days. The mice of the pVAX1-SAG1 group
also began to die from the third day on, and all had died by
day 8, (average04.70±0.60 days). Mice immunized with
pVAX1-GRA1-SAG1 began to die beginning on day 4;
however, three mice were still alive on day 10 (average0
7.60±0.74 days). This last group lived longer than the other
groups (P<0.05). The statistical significance between dif-
ferent groups was demonstrated by survival analysis (log-
rank statistic, Table 1). The data indicate that multicompo-
nent DNA vaccines, encoding T. gondii GRA1 and SAG1,
can increase the survival time of mice challenged with T.
gondii RH strain.
Anti-Toxoplasma IgG levels in BALB/c mice
To evaluate the immunogenicity of the GRA1 and SAG1
DNA vaccines, BALB/c mice were immunized with empty
vector or single- or two-gene vaccines. Mice were bled, and
anti-Toxoplasma IgG levels were determined by ELISA
4 weeks following the last vaccination (Fig. 4). The anti-
Toxoplasma IgG optical density (OD) value was 0.790±
0.083 in the pVAX1-GRA1 + pVAX1-SAG1 group, while
the values were 0.430±0.052 and 0.451±0.060 in pVAX1-
GRA1 and pVAX1-SAG1 groups, respectively. The OD
values were 0.310±0.071 in the control vector group and
0.252±0.080 for the PBS control. Using ANOVA statistical
analysis, the OD values in the pVAX1-GRA1 + pVAX1-
SAG1, pVAX1-GRA1, and pVAX1-SAG1 were significant-
ly higher than those in PBS control group (P<0.05). The
values for the pVAX1-GRA1 + pVAX1-SAG1 were higher
Fig. 1 Characterization of recombinant plasmids pVAX1-GRA1 and
pVAX1-SAG1 by PCR and restriction enzyme digestion. M DNA
marker, 1 pVAX1, 2 amplified fragment of SAG1 gene, 3 recombinant
plasmid pVAX1-SAG1 digested by Kpn I and EcoR I, 4 amplified
fragment of GRA1 gene, 5 recombinant plasmid pVAX1-GRA1
digested by Kpn I and EcoR I
Fig. 2 Expression of GRA1/
SAG1 antigen in mouse
macrophage
(immunocytochemistry, ×400).
Upper left RAW264.7, upper
right RAW264.7 transfected
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than those for pVAX1-SAG1 and pVAX1-GRA1 (P<0.05).
These results indicate that a multicomponent DNA vaccine,
encoding T. gondii GRA1 and SAG1, induces a strong anti-
T. gondii IgG antibody response.
Production of IFN-γ, IL-2, and IL-4 in sera from BALB/c
mice
To evaluate the role of cytokines in the cellular immune
response against T. gondii infection, IFN-γ, IL-2, and IL-4
serum levels in immunized mice were measured by ELISA
(Fig. 5). The IFN-γ levels in the pVAX1-GRA1 + pVAX1-
SAG1 (853.77±66.74 pg/ml), pVAX1 (679.63±44.79 pg/
ml), and pVAX1-SAG1 (669.78±50.42 pg/ml) groups were
higher relative to those of control group (598.74±67.50 pg/
ml) (P<0.05). The IFN-γ levels in the pVAX1-GRA1 +
pVAX1-SAG1 group were elevated relative to those of
pVAX1-GRA1 and pVAX1-SAG1 (P<0.05). IL-2 levels in
the pVAX1-GRA1 + pVAX1-SAG1 group (192.24±
19.90 pg/ml) were higher than those of empty pVAX1
vector (92.77±13.94 pg/ml) and PBS control (89.44±
10.66 pg/ml) (P<0.05). In contrast, the IL-4 levels of the
five groups were similar (P>0.05). The data show that the
DNA vaccine, encoding GRA1 and SAG1, is able to pro-
duce higher levels of IFN-γ and IL-2.
Percent change of CD4+/CD8+ T cells in splenocytes
from BALB/c mice immunized with DNA vaccines
Protection against T. gondii is dependent on both CD4+ and
CD8+ cells (Li et al. 2010). To evaluate the role of CD4+ and
CD8+ cells in the cellular immune response against T. gondii
challenge, the percent change of CD4+/CD8+ T cells in
splenocytes from immunized mice was measured by flow
cytometry (Table 2). Compared with PBS control, the per-
cent of CD4+ cells in the pVAX1-GRA1 + pVAX1-SAG1
(37.42±4.84 %), pVAX1-SAG1 (44.32±2.61 %), and
pVAX1-GRA1 (45.82±3.01 %) groups was reduced (P<
Fig. 3 Survival curves of
BALB/c mice injected with
50 μl PBS or immunized with
100 μg empty pVAX1, 100 μg
pVAX-GRA1, 100 μg pVAX1-
SAG1, 50 μg pVAX1-GRA1 +
50 μg pVAX1-SAG1, respec-
tively, and challenged with 105
tachyzoites of T. gondii RH
strain 4 weeks after last vacci-
nation. Each group contained
ten mice. Survival data were
recorded until the end of the
observation period
Table 1 Results of log-rank statistics for survival time of BALB/c mice challenged with 105 tachyzoites of T. gondii RH strain 4 weeks after last
vaccination (N010)
Group Control pVAX1 pVAX1-GRA1 pVAX1-SAG1 pVAX1-GRA1 + pVAX1-SAG1
Control – 1.07 (0.3000) 1.04 (0.3090) 0.33 (0.5680) 7.97 (0.0048)
pVAX1 1.07 (0.3000) – 2.98 (0.0840) 0.12 (0.7263) 8.11 (0.0044)
pVAX1-GRA1 1.04 (0.3090) 2.98 (0.0840) – 1.26 (0.2620) 9.97 (0.0016)
pVAX1-SAG1 0.33 (0.5680) 0.12 (0.7263) 1.26 (0.2620) – 8.10 (0.0044)
pVAX1-GRA1 + pVAX1-SAG1 7.97 (0.0048) 8.11 (0.0044) 9.97 (0.0016) 8.10 (0.0044) –
The values in the table are chi-square values tested by log-rank statistic of pairwise comparisons. The values in parentheses are significance values
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0.05). The percent of CD8+ cells in the pVAX1-GRA1 +
pVAX1-SAG1 group (34.94±5.30 %) increased relative to
that of pVAX1 or PBS control (P<0.05). The CD4+/CD8+
ratio of pVAX1-GRA1 + pVAX1-SAG1 (1.09±0.19 %),
pVAX1-SAG1 (1.56±0.22 %), and pVAX1-GRA1 (1.66±
0.13 %) groups decreased relative to that of pVAX1 (P<
0.05). The CD4+/CD8+ ratio of pVAX1-GRA1 + pVAX1-
SAG1 was lower than that observed for the pVAX1-GRA1
and pVAX1-SAG1 groups (P<0.05).
NK cell-killing activity in BALB/c splenocytes from mice
immunized with DNA vaccine
To test whether NK cells play an important role in the cellular
immune responses induced by the GRA1 and SAG1 vaccine,
the NK cell-killing activity of splenocytes was determined by
MTT assays (Fig. 6). The NK cell-killing rate of splenocytes
of pVAX1-GRA1 + pVAX1-SAG1, the pVAX1-GRA1, the
pVAX1-SAG1, the pVAX1 empty vector, and the PBS control
group was 64.15±7.71, 52.03±6.96, 55.95±7.37, 48.13±
4.58, and 46.81±3.96 %, respectively. ANOVA analysis indi-
cated that the increased killing of the pVAX1-GRA1 +
pVAX1-SAG1, pVAX1-GRA1, and pVAX1-SAG1 groups
were statistically significant relevant to the control group (P
<0.05). The killing rate of the pVAX1-GRA1 + pVAX1-
SAG1 NK cells was higher than that of the pVAX1-GRA1
and pVAX1-SAG1 NK cells (P<0.05).
Discussion
The potential for a multicomponent DNAvaccine, encoding T.
gondii GRA1 and SAG1 to induce protective immune
responses in BALB/c mice, was investigated. The results
indicate that the vaccine primes humoral and cellular





































       1:Control; 2:pVAX1; 3:pVAX1GRA1; 4:pVAX1SAG1; 5:pVAX1GRA1-pVAX1SAG1.
Group
Fig. 4 Levels of IgG antibody
in sera from BALB/c mice
immunized with single- or two-
gene DNA vaccines, empty
vector, or PBS (control group)
as measured by ELISA 4 weeks
after last vaccination. Each
group was composed of eight
mice
Fig. 5 Levels of IFN-γ, IL-2,
and IL-4 in sera from the
BALB/c mice immunized with
the single- or two-gene DNA
vaccine, the empty vector, or
PBS (control) as measured by
ELISA 4 weeks following the
last vaccination. Each group
was composed of eight mice
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The challenge dose may be a factor that influences the
observed protection level. In this study, we sought to assess
vaccine protection against a high-dose challenge (with regard
to mouse) because humans are not considered to be as sensi-
tive to Toxoplasma as mouse, especially at the lethal dose. The
lethal dose of 105 RH parasites in mouse (Fachado et al. 2003)
may not be lethal if the equivalent were used in humans.
Interestingly, even at this high-dose level, three mice vacci-
nated with the multicomponent vaccine were still alive on day
10; however, all control mice had died by day 5, and statistical
significance was observed. The results suggest that combined
immunization of pVAX1-GRA1 and pVAX1-SAG1 can sig-
nificantly prolong survival of mice challenged with T. gondii
RH strain, compared with the control. There was not an
obvious prolonged survival of mice challenged with T. gondii
RH strain when immunized with plasmid pVAX1-GRA1 or
pVAX1-SAG1 alone. These results suggest that a combined
GRA1 and SAG1 can enhance a protective effect against a
lethal T. gondii infection, consistent with current studies (Li et
al. 2010; Liu et al. 2009; Wang et al. 2009).
To explore the mechanisms of protective immunity in-
duced by the DNA vaccine encoding GRA1 and SAG1,
humoral and cellular immune responses were analyzed.
For humoral immune responses, our data showed that the
relative level of anti-T. gondii IgG antibody in mice immu-
nized with pVAX1-GRA1 or pVAX1-SAG1 was elevated,
comparing to controls, and it was further elevated by immu-
nization with pVAX1-GRA1 + pVAX1-SAG1, suggesting
that a DNA vaccine, encoding GRA1 and SAG1, could
produce stronger humoral immunity.
It has been shown that protection against T. gondii is
dependent on both CD4+ and CD8+ cells (Li et al. 2010).
CD8+ T cells constitute the major T cell subset involved in
acquired cellular immune protection against T. gondii (Tan et
al. 2011). In vivo T cell depletion experiments indicate that
CD8+ T cells are essential for survival of GRA1-vaccinated
C3H mice during acute phase of T. gondii infection, while
depletion of CD4+ T cells led to an increase in brain cyst
burden during the chronic phase of infection (Scorza et al.
2003). We observed that 4 weeks after the last vaccination, the
percentage of splenic CD8+ T cells in immunized mice in-
creased in the pVAX1-GRA1 + pVAX1-SAG1 group, while
pVAX1-GRA1- and pVAX1-SAG1-immunized mice did not
exhibit any significant change. The CD4+/CD8+ ratio was
reduced significantly. These data suggest that the immune
protection against T. gondii challenge is elicited by multicom-
ponent pVAX1-GRA1 + pVAX1-SAG1, and that it is medi-
ated primarily through induction of CD8+ T subsets and a
Th1-type cellular immune response.
NK cells are a kind of lymphocyte with powerful cyto-
toxicity and play an important role in innate immunity. We
found that NK cell-killing activity of pVAX1-GRA1 +
pVAX1-SAG1, pVAX1-SAG1, and pVAX1-GRA1 groups
were all higher than that of controls, while the cytotoxicity
of the pVAX1-GRA1 + pVAX1-SAG1 group was higher
than that of pVAX1-GRA1 and pVAX1-SAG1, suggesting
that combined GRA1 and SAG1 is more effective at en-
hancing NK cell activity.
Cytokines play an important role in Th cell function.
Previous studies have shown that IFN-γ can promote Th1
differentiation, and that IL-4 can induce development of
Th2 cells (Maggi et al. 1992). Th1 cells can further stimulate
Table 2 Flow cytometry analy-
sis of T lymphocyte subsets in
splenocytes from BALB/c mice
4 weeks after last vaccination
(N08)
aCompared with the PBS control
group, P<0.05
bCompared with the pVAX1
group, P<0.05
Group T 1ymphocyte subsets
CD4+ (%) CD8+ (%) CD4+/CD8+
PBS control 48.59±1.85 26.91±2.12 1.81±0.14
pVAX1 48.01±2.32 26.35±1.69 1.83±0.12
pVAX1-GRA1 45.82±3.01a 27.82±3.24 1.66±0.13b
pVAX1-SAG1 44.32±2.61a, b 28.89±4.87 1.56±0.22a, b
pVAX1-GRA1 + pVAX1-SAG1 37.42±4.84a, b 34.94±5.30a, b 1.09±0.19a, b
Fig. 6 The NK cell-killing activity of splenocytes from BALB/c mice
4 weeks after the last vaccination. Each group was composed of eight mice
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macrophages and CTL through IFN-γ, while Th2 cells regu-
late B cell helper activities by IL-4. Furthermore, IFN-γ and
IL-2 are important stimulatory cytokines involved in the pro-
tection against parasitic infection. T cells and NK cells are the
primary producers of IFN-γ, which enhances NK cell-killing
activity and activates mononuclear macrophages to kill T.
gondii intracellularly. IL-2 can activate the cytotoxic activity
of T cells and facilitate production of various cytokines, such
as IFN-γ. IL-2 also stimulates NK cell cytotoxicity, while IL-4
is thought to downregulate the inflammatory immune re-
sponse (Matowicka-Karna et al. 2009; Suzuki et al. 1989,
1988). To evaluate the effects of vaccine pVAX1-GRA1 and
pVAX1-SAG1, three cytokines were monitored. Our results
indicate that pVAX1-GRA1 and pVAX1-SAG1 are capable of
stimulating high levels of IFN-γ and IL-2, although IL-4
levels were similar across all groups, suggesting that vaccina-
tion was preferentially driving a Th1-type response. The emp-
ty pVAX1 plasmid appeared to also stimulate IFN-γ secretion,
suggesting that the DNA macromolecule itself may function
as an immunological adjuvant and induce nonspecific stimu-
lation on the immune system.
In summary, our results demonstrate that a multicompo-
nent DNA vaccine, encoding T. gondii GRA1 and SAG1,
primes the immune system to generate a stronger humoral
and cellular immune response and enhances protection
against a T. gondii challenge. This combination vaccine
may, therefore, provide a more effective means to combat
troublesome T. gondii infections.
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